Dr. Ruoxi Hong 洪若熙
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Personalized breast cancer treatment and management, including chemotherapy, endocrine therapy, and targeted therapy. Also provides genetic counseling, diagnosis, screening, and participation in clinical trials for new anti-tumor drugs.
Dr. Hong holds a medical doctorate from Peking Union Medical College (Tsinghua University School of Medicine). Dr. Hong is a Chief Physician in the Department of Medical Oncology at Sun Yat-sen University Cancer Center.
Name order: in Chinese the family name comes first (Hong Ruoxi). Papers usually list the name as Ruoxi Hong or Hong R.
Selected publications
58 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Cancer Res, 2026 (senior author): Palbociclib, Fulvestrant, Trastuzumab, and Pyrotinib for Patients with Advanced Breast Cancer with Brain Metastases: A Prospective Multicenter Phase 2 Trial. PubMed 43013351
- Genome Med, 2026 (first author): Geospatial genetic evolution and phenotypic plasticity in triple-negative breast cancer. PubMed 42271485
- J Clin Oncol, 2025 (first author): Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial. PubMed 39746176
- Cancer Immunol Immunother, 2024 (senior author): Distribution characteristics of immune infiltration and lymphovascular invasion in patients with breast cancer skin recurrence. PubMed 39235656
- Breast Cancer Res Treat, 2024 (first author): Multi-omics portrait of ductal carcinoma in situ in young women. PubMed 38704773
- NPJ Breast Cancer, 2024 (senior author): Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. PubMed 38871705
- Cancer Commun (Lond), 2022 (first author): Breast cancer: an up-to-date review and future perspectives. PubMed 36074908
- Cancer Commun (Lond), 2021 (first author): Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. PubMed 33528890
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion